In addition, the site will have the capability to produce glass prefillable syringes for GLP-1 therapies, for example to treat diseases such as diabetes or obesity.

The project, Schott Pharma said, will create 401 jobs and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027.

“As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, Schott Pharma will be able to fill those orders quickly and efficiently here in the US,” said Andreas Reisse, CEO of Schott Pharma. “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain,” Reisse added.